CEBPA and acute myeloid leukemia: In 2024 among 1010 CEBPA-mutant adult AML patients detailed mutational analysis (bZIPInDel, bZIPSTOP, bZIPms, TAD, and smCEBPA vs. dmCEBPA mutations) revealed only patients with bZIPInDel mutation had significatly higher CR and OS29.